Phase 3 Clinical Trials With Primary Completion Dates in June 2016
This is a list of Phase 3 trials with primary completion dates in June 2016 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| ACOR | Acorda Therapeutics, Inc. | 2016-06-01 | Phase 3 | NCT02240030 | Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes |
| AMPE | Ampio Pharmaceuticals, Inc. | 2016-06-01 | Phase 3 | NCT02556710 | AP-003-B Study to Evaluate the Efficacy And Safety Of An Intra-Articular Injection Of Ampion⢠In Adults With Pain With Osteoarthritis Of The Knee |
| ARRY | Array BioPharma Inc. | 2016-06-01 | Phase 3 | NCT01909453 | Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma |
| ARRY | Array BioPharma Inc. | 2016-06-01 | Phase 3 | NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer |
| CYAD | Celyad SA | 2016-06-01 | Phase 3 | NCT02317458 | Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-2) Trial THE CHART-2 TRIAL |
| DRRX | Durect Corporation | 2016-06-01 | Phase 3 | NCT02450890 | Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD |
| DSCI | Derma Sciences, Inc. | 2016-06-01 | Phase 3 | NCT01840085 | Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use |
| EBIO | Eleven Biotherapeutics, Inc. | 2016-06-01 | Phase 3 | NCT02405039 | Study of EBI-005 in Dry Eye Disease (DED) |
| FGEN | FibroGen, Inc | 2016-06-01 | Phase 3 | NCT01887600 | Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis |
| INSY | Insys Therapeutics, Inc. | 2016-06-01 | Phase 3 | NCT02634788 | Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain |
| LJPC | La Jolla Pharmaceutical Company | 2016-06-01 | Phase 3 | NCT02338843 | A Phase 3 Study of LJPC-501 in Patients With Catecholamine-Resistant Hypotension |
| MSTX | Mast Therapeutics, Inc. | 2016-06-01 | Phase 3 | NCT02449616 | Evaluation of Repeat Administration of Purified Poloxamer 188 |
| MYGN | Myriad Genetics, Inc. | 2016-06-01 | Phase 3 | NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |
| NLNK | NewLink Genetics Corporation | 2016-06-01 | Phase 3 | NCT01072981 | Immunotherapy Study for Surgically Resected Pancreatic Cancer |
| ONTX | Onconova Therapeutics, Inc. | 2016-06-01 | Phase 3 | NCT01928537 | Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine |
| PRAH | PRA Health Sciences, Inc. | 2016-06-01 | Phase 3 | NCT02333071 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension |
| PTN | Palatin Technologies, Inc. | 2016-06-01 | Phase 3 | NCT02333071 | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial With an Open-label Extension |
| RDY | Dr. Reddy's Laboratories Ltd | 2016-06-01 | Phase 3 | NCT02569853 | DFN-11 Injection in Episodic Migraine With or Without Aura |
| RIGL | Rigel Pharmaceuticals, Inc. | 2016-06-01 | Phase 3 | NCT02076412 | A Efficacy and Safety Study of Fostamatinib in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| RIGL | Rigel Pharmaceuticals, Inc. | 2016-06-01 | Phase 3 | NCT02076399 | A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) |
| RTRX | Retrophin, Inc. | 2016-06-01 | Phase 3 | NCT01438411 | Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid Synthesis |
| RVNC | Revance Therapeutics, Inc. | 2016-06-01 | Phase 3 | NCT02580370 | Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines |
| SGYP | Synergy Pharmaceuticals, Inc. | 2016-06-01 | Phase 3 | NCT02387359 | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) |
| SGYPU | Synergy Pharmaceuticals, Inc. | 2016-06-01 | Phase 3 | NCT02387359 | The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C) |
| TBPH | Theravance Biopharma, Inc. | 2016-06-01 | Phase 3 | NCT02512510 | Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) |
| TBPH | Theravance Biopharma, Inc. | 2016-06-01 | Phase 3 | NCT02459080 | Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) |
| TSRO | TESARO, Inc. | 2016-06-01 | Phase 3 | NCT01847274 | A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer |